teclistamab-cqyv (Tecvayli)
Jump to navigation
Jump to search
Indications
- relapsed/refractory multiple myeloma (FDA-approved)[2]
* overall response rate of 65% over a median follow-up of 6 months
Dosage
- intravenous or subcutaneous administration
- 1500 ug/kg after 60 ug/kg & 300 ug/kg step-up doses
Adverse effects
- treatment related adverse effects common (up to 80%)
- neutropenia (40%)
- anemia (28%)
- thrombocytopenia (20%)
- cytokine release syndrome (70%).
Mechanism of action
- bispecific antibody
- binds B-cell maturation antigen (BCMA) & CD3 to redirect T cells to multiple myeloma cells
More general terms
References
- ↑ Bassett M Bispecific Antibody Shows Promise in R/R Multiple Myeloma. Investigational agent yielded responses in nearly two-thirds of patients MedPage Today August 20, 2021 https://www.medpagetoday.com/hematologyoncology/myeloma/94157
Usmani SZ, Garfall AL, van de Donk NWC Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021 Aug 10;S0140-6736(21)01338-6 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34388396 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01338-6/fulltext - ↑ 2.0 2.1 Bankhead C FDA Broadens Options for Relapsed/Refractory Multiple Myeloma With Teclistamab. Bispecific antibody achieved durable responses in a majority of heavily pretreated patients. MedPage Today October 25, 2022 https://www.medpagetoday.com/hematologyoncology/myeloma/101422